Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab for Active Non-infectious Intermediate, Posterior, or Pan-uveitis (Randomized Double-masked Placebo-controlled Phase 3)
2012-001610-42Phase 3Terminated
- Sponsor
- XOMA
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in uveitis comparing gevokizumab with placebo (2 arms). Primary endpoint: Proportion of responders at Day 56. Started Sep 2012; status: terminated.
02
Drugs
gevokizumab
03
Conditions
uveitis
Beyond the preview
Go deeper on 2012-001610-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001610-42.